An evaluation of the cardiotoxicity of imatinib mesylate.

Abstract

We studied 103 consecutive patients with chronic myeloid leukaemia on treatment with imatinib (IM) and 57 patients with chronic myeloproliferative disorders not treated with IM in order to evaluate its cardiotoxicity. There was no statistical difference regarding cardiac symptoms and signs, BNP levels and echocardiographic measurements for IM and control groups, except for peripheral oedema, more frequent in the IM group. Four patients in the IM group presented a BNP level >100pg/ml, one of them with depressed LVEF. IM was not related to systematic deterioration of cardiac function, but there is still a possibility of isolated cases of cardiotoxicity.

• Authors: Antonio Luiz Ribeiro, Milena Soriano Marcolino, Henrique N S Bittencourt, Márcia M Barbosa, Maria do Carmo P Nunes, Vitor Fonseca Xavier, Nelma C D Clementino
• Journal: Leukemia research (Leuk Res) Vol. 32 Issue 12 Pg. 1809-14 (Dec 2008) ISSN: 0145-2126 [Print] England
• PMID: 18495246 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Benzamides
• Cardiotoxins
• Piperazines
• Pyrimidines
• Imatinib Mesylate

Topics

• Aged
• Antineoplastic Agents (therapeutic use, toxicity)
• Atrial Fibrillation (drug therapy, physiopathology)
• Atrial Function, Left (drug effects)
• Atrial Function, Right (drug effects)
• Benzamides
• Blood Pressure (drug effects)
• Cardiotoxins (toxicity)
• Electrocardiography (drug effects)
• Heart Rate (drug effects)
• Humans
• Imatinib Mesylate
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)
• Male
• Middle Aged
• Myeloproliferative Disorders (drug therapy)
• Piperazines (therapeutic use, toxicity)
• Pyrimidines (therapeutic use, toxicity)